No results for ‘’
Panacea Biotec Ltd
₹397.65
(2.32%)
Tue, 15 Sept 2026, 09:58 am
Health Technology
Pharmaceuticals: Major
24.5KPanacea Biotec EV/EBITDA Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 41.13 | 19.02 | 17.68 | 0 | 19.26 | 7.95 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32.18 | 0 | 0 | 0.84 | 0 | 0 | 0 |
| Price to book ratio | 14.15 | 5.09 | 3.22 | 0.64 | 2.10 | 1.72 | 0.57 | 1.22 | 1.13 | 1.89 | 1.32 | 2.77 | 5.30 | 3.46 | 3.37 | 0 | 1.04 | 0.79 | 0.88 | 3.23 |
| Price to sales ratio | 4.21 | 3.30 | 2.82 | 0.53 | 1.75 | 1.01 | 0.72 | 1.33 | 1.17 | 1.27 | 0.91 | 1.85 | 2.79 | 2.68 | 1.25 | 1.76 | 1.38 | 1.45 | 1.34 | 5.47 |
| Price to cash flow ratio | 14.85 | 17.25 | 38.79 | 0 | 54.85 | 28.14 | 2.95 | 0 | 0 | 52.42 | 34.22 | 29.65 | 191.82 | 30.54 | 0 | 100.62 | 0 | 0 | 58.76 | 0 |
| Enterprise value | 2515Cr | 2810Cr | 2615Cr | 1051Cr | 2235Cr | 1967Cr | 1367Cr | 1706Cr | 1625Cr | 1919Cr | 1650Cr | 1974Cr | 2549Cr | 1834Cr | 1320Cr | 1767Cr | 351Cr | 441Cr | 580Cr | 2546Cr |
| Enterprise value to EBITDA ratio | 20.62 | 12.02 | 11.80 | 4.62 | 17.60 | 8.60 | 0 | 0 | 0 | 32.10 | 15.53 | 31.60 | 29.62 | 0 | 24.10 | 22.55 | 0 | 0 | 25.59 | 0 |
| Debt to equity ratio | 2.39 | 0.40 | 0.57 | 1.14 | 1 | 1.33 | 1 | 1.57 | 2.07 | 2.34 | 2.43 | 2.79 | 3.05 | 1.85 | 3.73 | 0 | 0.04 | 0.02 | 0.02 | 0.03 |
| Return on equity % | 25.89 | 37.77 | 21.77 | -9.98 | 12.39 | 21.41 | -26.99 | -31.23 | -19.70 | -21.66 | -3.98 | -9.75 | -21.55 | 12.43 | -68.40 | 0 | 332.84 | -3.93 | -0.14 | -1 |
Panacea Biotec Ltd Enterprise Value to EBITDA Ratio
The Panacea Biotec Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Panacea Biotec Ltd's valuation, profitability, and overall financial performance. Tracking the Panacea Biotec Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Panacea Biotec Ltd (NSE: PANACEABIO, BSE: 531349) is currently trading at ₹397.65, with a market capitalization of ₹2438.09Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Panacea Biotec Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.
Panacea Biotec Ltd Enterprise Value to EBITDA Ratio Current Value
The current Panacea Biotec Ltd Enterprise Value to EBITDA Ratio stands at 0.
The Panacea Biotec Ltd Enterprise Value to EBITDA Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Panacea Biotec Ltd Enterprise Value to EBITDA Ratio Historical Trend
The Panacea Biotec Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:
- 2024: 0
- 2023: 25.59
- 2022: 0
- 2021: 0
- 2020: 22.55
The decline in Panacea Biotec Ltd Enterprise Value to EBITDA Ratio indicates improving financial efficiency or better earnings growth.
What Panacea Biotec Ltd Enterprise Value to EBITDA Ratio Indicates for Investors
The Panacea Biotec Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Panacea Biotec Ltd.
Panacea Biotec Ltd Enterprise Value to EBITDA Ratio Analysis Summary
The Panacea Biotec Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Panacea Biotec Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Panacea Biotec Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.